A meta-analytic review of polyunsaturated fatty acid compositions in dementia

Pao Yen Lin, Chih Chiang Chiu, Shih Yi Huang, Kuan Pin Su

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

Objective: To determine whether the levels of docosahexaenoic acid (DHA), eicosapentaenoic acid (EPA), arachidonic acid (AA), total n-3 polyunsaturated fatty acids (PUFAs), and total n-6 PUFAs were changed in patients with dementia or predementia syndrome. Data Sources: PubMed was searched for studies from first date available to July 2011 using the following search terms: (dementia OR cognitive impairment OR mild cognitive impairment) AND (omega-3 OR omega-6 OR polyunsaturated fatty acid OR docosahexaenoic acid OR DHA OR eicosapentaenoic acid OR EPA). The search was limited to literature in English and to human studies. The references of relevant articles and review articles were searched for citations not indexed in PubMed. Study Selection: Studies were included if they measured levels of EPA, DHA, AA, total n-3 PUFAs, or total n-6 PUFAs from peripheral blood tissues in subjects with cognitive deficits (dementia or predementia syndrome) and elderly controls and were published in peer-reviewed journals. The search yielded 10 articles including 2,280 subjects. Data Extraction: The study design, sample size, PUFA levels for both patients and control subjects, sampling tissue, diagnoses and diagnostic criteria for cognitive deficits, and distribution of mean age and gender of included subjects were extracted for each study. Results: In a random-effects model, we found that the levels of EPA (effect size [ES] = -0.47, P <.0001), DHA (ES = -0.33, P = .017), and total n-3 PUFAs (ES = -0.46, P = .001) were decreased in patients with dementia. However, the levels of EPA (ES = -0.44, P = .002), but not DHA or other PUFAs, were significantly lower in patients with predementia syndrome. Conclusions: Our results support the important role of n-3 PUFAs in the pathophysiology of dementia. In addition, the analyses of predementia studies indicate that EPA might be not only a disease-state marker but also a risk factor for cognitive impairment.

Original languageEnglish
Pages (from-to)1245-1254
Number of pages10
JournalJournal of Clinical Psychiatry
Volume73
Issue number9
DOIs
Publication statusPublished - 2012

Fingerprint

Eicosapentaenoic Acid
Unsaturated Fatty Acids
Docosahexaenoic Acids
Dementia
Omega-3 Fatty Acids
PubMed
Arachidonic Acid
Omega-6 Fatty Acids
Information Storage and Retrieval
Age Distribution
Sample Size
Cognitive Dysfunction

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

A meta-analytic review of polyunsaturated fatty acid compositions in dementia. / Lin, Pao Yen; Chiu, Chih Chiang; Huang, Shih Yi; Su, Kuan Pin.

In: Journal of Clinical Psychiatry, Vol. 73, No. 9, 2012, p. 1245-1254.

Research output: Contribution to journalArticle

Lin, Pao Yen ; Chiu, Chih Chiang ; Huang, Shih Yi ; Su, Kuan Pin. / A meta-analytic review of polyunsaturated fatty acid compositions in dementia. In: Journal of Clinical Psychiatry. 2012 ; Vol. 73, No. 9. pp. 1245-1254.
@article{28c5e42e4e0b4fe4a9b1fddccce8d1c4,
title = "A meta-analytic review of polyunsaturated fatty acid compositions in dementia",
abstract = "Objective: To determine whether the levels of docosahexaenoic acid (DHA), eicosapentaenoic acid (EPA), arachidonic acid (AA), total n-3 polyunsaturated fatty acids (PUFAs), and total n-6 PUFAs were changed in patients with dementia or predementia syndrome. Data Sources: PubMed was searched for studies from first date available to July 2011 using the following search terms: (dementia OR cognitive impairment OR mild cognitive impairment) AND (omega-3 OR omega-6 OR polyunsaturated fatty acid OR docosahexaenoic acid OR DHA OR eicosapentaenoic acid OR EPA). The search was limited to literature in English and to human studies. The references of relevant articles and review articles were searched for citations not indexed in PubMed. Study Selection: Studies were included if they measured levels of EPA, DHA, AA, total n-3 PUFAs, or total n-6 PUFAs from peripheral blood tissues in subjects with cognitive deficits (dementia or predementia syndrome) and elderly controls and were published in peer-reviewed journals. The search yielded 10 articles including 2,280 subjects. Data Extraction: The study design, sample size, PUFA levels for both patients and control subjects, sampling tissue, diagnoses and diagnostic criteria for cognitive deficits, and distribution of mean age and gender of included subjects were extracted for each study. Results: In a random-effects model, we found that the levels of EPA (effect size [ES] = -0.47, P <.0001), DHA (ES = -0.33, P = .017), and total n-3 PUFAs (ES = -0.46, P = .001) were decreased in patients with dementia. However, the levels of EPA (ES = -0.44, P = .002), but not DHA or other PUFAs, were significantly lower in patients with predementia syndrome. Conclusions: Our results support the important role of n-3 PUFAs in the pathophysiology of dementia. In addition, the analyses of predementia studies indicate that EPA might be not only a disease-state marker but also a risk factor for cognitive impairment.",
author = "Lin, {Pao Yen} and Chiu, {Chih Chiang} and Huang, {Shih Yi} and Su, {Kuan Pin}",
year = "2012",
doi = "10.4088/JCP.11r07546",
language = "English",
volume = "73",
pages = "1245--1254",
journal = "Journal of Clinical Psychiatry",
issn = "0160-6689",
publisher = "Physicians Postgraduate Press Inc.",
number = "9",

}

TY - JOUR

T1 - A meta-analytic review of polyunsaturated fatty acid compositions in dementia

AU - Lin, Pao Yen

AU - Chiu, Chih Chiang

AU - Huang, Shih Yi

AU - Su, Kuan Pin

PY - 2012

Y1 - 2012

N2 - Objective: To determine whether the levels of docosahexaenoic acid (DHA), eicosapentaenoic acid (EPA), arachidonic acid (AA), total n-3 polyunsaturated fatty acids (PUFAs), and total n-6 PUFAs were changed in patients with dementia or predementia syndrome. Data Sources: PubMed was searched for studies from first date available to July 2011 using the following search terms: (dementia OR cognitive impairment OR mild cognitive impairment) AND (omega-3 OR omega-6 OR polyunsaturated fatty acid OR docosahexaenoic acid OR DHA OR eicosapentaenoic acid OR EPA). The search was limited to literature in English and to human studies. The references of relevant articles and review articles were searched for citations not indexed in PubMed. Study Selection: Studies were included if they measured levels of EPA, DHA, AA, total n-3 PUFAs, or total n-6 PUFAs from peripheral blood tissues in subjects with cognitive deficits (dementia or predementia syndrome) and elderly controls and were published in peer-reviewed journals. The search yielded 10 articles including 2,280 subjects. Data Extraction: The study design, sample size, PUFA levels for both patients and control subjects, sampling tissue, diagnoses and diagnostic criteria for cognitive deficits, and distribution of mean age and gender of included subjects were extracted for each study. Results: In a random-effects model, we found that the levels of EPA (effect size [ES] = -0.47, P <.0001), DHA (ES = -0.33, P = .017), and total n-3 PUFAs (ES = -0.46, P = .001) were decreased in patients with dementia. However, the levels of EPA (ES = -0.44, P = .002), but not DHA or other PUFAs, were significantly lower in patients with predementia syndrome. Conclusions: Our results support the important role of n-3 PUFAs in the pathophysiology of dementia. In addition, the analyses of predementia studies indicate that EPA might be not only a disease-state marker but also a risk factor for cognitive impairment.

AB - Objective: To determine whether the levels of docosahexaenoic acid (DHA), eicosapentaenoic acid (EPA), arachidonic acid (AA), total n-3 polyunsaturated fatty acids (PUFAs), and total n-6 PUFAs were changed in patients with dementia or predementia syndrome. Data Sources: PubMed was searched for studies from first date available to July 2011 using the following search terms: (dementia OR cognitive impairment OR mild cognitive impairment) AND (omega-3 OR omega-6 OR polyunsaturated fatty acid OR docosahexaenoic acid OR DHA OR eicosapentaenoic acid OR EPA). The search was limited to literature in English and to human studies. The references of relevant articles and review articles were searched for citations not indexed in PubMed. Study Selection: Studies were included if they measured levels of EPA, DHA, AA, total n-3 PUFAs, or total n-6 PUFAs from peripheral blood tissues in subjects with cognitive deficits (dementia or predementia syndrome) and elderly controls and were published in peer-reviewed journals. The search yielded 10 articles including 2,280 subjects. Data Extraction: The study design, sample size, PUFA levels for both patients and control subjects, sampling tissue, diagnoses and diagnostic criteria for cognitive deficits, and distribution of mean age and gender of included subjects were extracted for each study. Results: In a random-effects model, we found that the levels of EPA (effect size [ES] = -0.47, P <.0001), DHA (ES = -0.33, P = .017), and total n-3 PUFAs (ES = -0.46, P = .001) were decreased in patients with dementia. However, the levels of EPA (ES = -0.44, P = .002), but not DHA or other PUFAs, were significantly lower in patients with predementia syndrome. Conclusions: Our results support the important role of n-3 PUFAs in the pathophysiology of dementia. In addition, the analyses of predementia studies indicate that EPA might be not only a disease-state marker but also a risk factor for cognitive impairment.

UR - http://www.scopus.com/inward/record.url?scp=84866513402&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866513402&partnerID=8YFLogxK

U2 - 10.4088/JCP.11r07546

DO - 10.4088/JCP.11r07546

M3 - Article

C2 - 22938939

AN - SCOPUS:84866513402

VL - 73

SP - 1245

EP - 1254

JO - Journal of Clinical Psychiatry

JF - Journal of Clinical Psychiatry

SN - 0160-6689

IS - 9

ER -